Search company, investor...

Lead Pharma


Project Finance | Alive

Total Raised


Last Raised

$11.86M | 2 yrs ago

About Lead Pharma

Lead Pharma is a spinoff from the Hubrecht Institute and the University Medical Center Utrecht, developing innovative small-molecule therapies for patients with autoimmune disease or cancer.

Headquarters Location

RK-building, Industrielaan 63

Oss, 5349 AE,


Missing: Lead Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Lead Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Lead Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lead Pharma is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Lead Pharma Patents

Lead Pharma has filed 1 patent.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Autoimmune diseases, Transcription factors, Monoclonal antibodies, Immunology, Immune system


Application Date


Grant Date



Related Topics

Autoimmune diseases, Transcription factors, Monoclonal antibodies, Immunology, Immune system



Latest Lead Pharma News

Funding round-up: Nowatch, Amili, TILT Biotherapeutics, Lead Pharma and Oxeltis, META Pharmaceuticals

Jun 20, 2022

China: META Pharmaceuticals, China’s first immunometabolism-based small-molecule drug discovery company, announced two consecutive Seed and Pre-A funding rounds totalling US$15m. Investors include Forcefield Ventures, XtalPi, IMO Ventures, and Tiantu Capital. In combining discoveries in immunometabolism and artificial intelligence (AI), META Pharmaceuticals has built an AI-powered metabolic target discovery platform and aims to develop the next generation of safer and […]

Lead Pharma Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Lead Pharma Rank

Lead Pharma Frequently Asked Questions (FAQ)

  • Where is Lead Pharma's headquarters?

    Lead Pharma's headquarters is located at RK-building, Industrielaan 63, Oss.

  • What is Lead Pharma's latest funding round?

    Lead Pharma's latest funding round is Project Finance.

  • How much did Lead Pharma raise?

    Lead Pharma raised a total of $11.86M.

  • Who are the investors of Lead Pharma?

    Investors of Lead Pharma include Roche Holding, PPM Oost, TechnoStars and Pamgene.

  • Who are Lead Pharma's competitors?

    Competitors of Lead Pharma include FirstString Research, OcuNexus Therapeutics, CoImmune, Momenta Pharmaceuticals, Regulus Therapeutics and 13 more.

Compare Lead Pharma to Competitors


Nanotope is a regenerative medicine company that leverages a core set of technologies to address multiple therapeutic markets. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for wound healing and the treatment of peripheral artery disease.n

Ascent Therapeutics

Ascent Therapeutics is a biopharmaceutical company developing a approach to the treatment of human disease that rapidly generates pharmaceuticals critical to many disease processes.

OcuNexus Therapeutics

OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.

Regentis Biomaterials

Regentis Biomaterials is focused on developing and commercializing hydrogels for tissue regeneration. The Gelrin hydrogel platform is a matrix of polyethylene glycol diacrylate (PEG-DA) and denatured fibrinogen, combining the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications. The company's flagship product, GelrinC, for the treatment of articular cartilage lesions, is currently in clinical trials.

Juventas Therapeutics

Juventas Therapeutics, formerly AcelleRx Therapeutics, Juventas Therapeutics is a privately held, clinical stage biotechnology company focused on developing non-viral gene therapies to treat advanced cardiovascular diseases. The Company's lead product candidate, JVS-100, is a non-viral gene therapy undergoing evaluation in clinical studies for the treatment of advanced cardiovascular diseases.

Rimon Therapeutics

Rimon Therapeutics, through the application of its polymer chemistry platform, is developing therapeutics to address unmet needs in important disease indicators with large markets. Rimon's therapeutic polymers - trademarked Theramers - are in that they deliver therapeutic effect without incorporating or releasing drugs. Theramers are intended to be used as solids-scaffolds, microbeeds and coatings - acting locally, without systemic consequences.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.